Results from the Registry of Atrial Fibrillation (AFABE): Gap between Undiagnosed and Registered Atrial Fibrillation in Adults - Ineffectiveness of Oral Anticoagulation Treatment with VKA

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Panisello Tafalla, Anna ^a   Clua Espuny, Josep Lluís ^b   Gil Guillen, Vicente F ^c   González Henares, Antonia ^b   Queralt Tomas, María Lluisa ^b   López Pablo, Carlos ^d   Lucas Noll, Jorgina ^b   Lechuga Duran, Iñigo ^d   Ripolles Vicente, Rosa ^b   Carot Domenech, Jesús ^e   López, Miquel Gallofré ^b  

^a Institut Català Salut   (Spain)

^b GENERALITAT DE CATALUNYA   (Spain)

^c MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^d INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

^e HOSPITAL VERGE DE LA CINTA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; VITAMIN K GROUP;

ADULT; AGED; ANTAGONISTS AND INHIBITORS; ATRIAL FIBRILLATION; CLINICAL TRIAL; FEMALE; HUMAN; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PREVALENCE; REGISTER; RISK FACTOR; SPAIN; SURVIVAL ANALYSIS;

ADMINISTRATION, ORAL; ADULT; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; HUMANS; MALE; PREVALENCE; REGISTRIES; RISK FACTORS; SPAIN; SURVIVAL ANALYSIS; VITAMIN K;

EID: 84953923709     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/134756     Document Type: Article

References (51)

1. EuropeanHeart RhythmAssociation, EuropeanAssociation for Cardio-Thoracic Surgery, A. J. Camm et al., "Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC), " European Heart Journal, vol. 31, no. 19, pp. 2369-2429, 2010.
2. J. Heeringa, D. A. M. van der Kuip, A. Hofman et al., "Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study, " European Heart Journal, vol. 27, no. 8, pp. 949-953, 2006.
3. H. Stefansdottir, T. Aspelund, V. Gudnason, and D. O. Arnar, "Trends in the incidence and prevalence of atrial fibrillation in Iceland and future projections, " Europace, vol. 13, no. 8, pp. 1110-1117, 2011.
4. P. Harmsen, L. Wilhelmsen, and A. Jacobsson, "Stroke incidence and mortality rates 1987 to 2006 related to secular trends of cardiovascular risk factors in Gothenburg, Sweden, " Stroke, vol. 40, no. 8, pp. 2691-2697, 2009.
5. W. P. Wodchis, R. S. Bhatia, K. Leblanc, N. Meshkat, and D. Morra, "A review of the cost of atrial fibrillation, " Value in Health, vol. 15, no. 2, pp. 240-248, 2012.
6. Y. Miyasaka, M. E. Barnes, B. J. Gersh et al., "Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence, " Circulation, vol. 114, no. 2, pp. 119-125, 2006.
7. G. V. Naccarelli, H. Varker, J. Lin, andK. L. Schulman, "Increasing prevalence of atrial fibrillation and flutter in the United States, "The American Journal of Cardiology, vol. 104, no. 11, pp. 1534-1539, 2009.
8. J. L. Clua-Espuny, R. Bosch-Princep, A. Roso-Llorach et al., "Diagnosed, undiagnosed and overall atrial fibrillation research on population over 60 year-old. AFABE study, " Cardiovascular System, vol. 2, no. 2, 2014.
9. A. Samol, M. Masin, R. Gellner et al., "Prevalence of unknown atrial fibrillation in patients with risk factors, " Europace, vol. 15, no. 5, pp. 657-662, 2013.
10. J. Oldgren, J. S. Healey, M. Ezekowitz et al., "Variations in cause and management of atrial fibrillation in a prospective registry of 15, 400 emergency department patients in 46 countries: the RE-LY atrial fibrillation registry, " Circulation, vol. 129, no. 15, pp. 1568-1576, 2014.
11. J. P. Casciano, Z. J. Dotiwala, B. C. Martin, and W. J. Kwong, "The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective, " Journal of Managed Care Pharmacy, vol. 19, no. 4, pp. 302-316, 2013.
12. C. L. Morgan, P. McEwan, A. Tukiendorf, P. A. Robinson, A. Clemens, and J.M. Plumb, "Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control, " Thrombosis Research, vol. 124, no. 1, pp. 37-41, 2009.
13. J. L. Clua-Espuny, I. Lechuga-Duran, R. Bosch-Princep et al., "Prevalencia de la fibrilación auricular desconocida y la no tratada con anticoagulantes. Estudio AFABE, " Revista Española de Cardiología, vol. 66, no. 7, pp. 545-552, 2013.
14. B. F. Gage, A. D. Waterman, W. Shannon, M. Boechler, M. W. Rich, and M. J. Radford, "Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation, " The Journal of the AmericanMedical Association, vol. 285, no. 22, pp. 2864-2870, 2001.
15. B. Pamukcu, G. Y. H. Lip, and D. A. Lane, "Simplifying stroke risk stratification in atrial fibrillation patients: Implications of the CHA2DS2-VASc risk stratification scores, " Age and Ageing, vol. 39, no. 5, pp. 533-535, 2010.
16. R. Pisters, D. A. Lane, R. Nieuwlaat, C. B. de vos, H. J. G. M. Crijns, and G. Y. H. Lip, "A novel user-friendly score (HASBLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the euro heart survey, " Chest, vol. 138, no. 5, pp. 1093-1100, 2010.
17. G. Y. H. Lip, "Implications of the CHA2DS2?VASc and HASBLED scores for thromboprophylaxis in atrial fibrillation, " The American Journal of Medicine, vol. 124, no. 2, pp. 111-114, 2011.
18. J. B. Olesen, G. Y. Lip, M. L. Hansen et al., "Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study, " British Medical Journal, vol. 342, article d124, 2011.
19. L. Friberg, M. Rosenqvist, and G. Y. H. Lip, "Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study, " European Heart Journal, vol. 33, no. 12, pp. 1500-1510, 2012.
20. L. Schmitt, J. Speckman, and J. Ansell, "Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-Therapeutic range, " Journal of Thrombosis andThrombolysis, vol. 15, no. 3, pp. 213-216, 2003.
21. S. Apostolakis, R. M. Sullivan, B. Olshansky, and G. Y. H. Lip, "Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score, " Chest, vol. 144, no. 5, pp. 1555-1563, 2013.
22. D. A. Fitzmaurice, "Routine screening for detection of atrial fibrillation?" Future Cardiology, vol. 5, no. 3, pp. 213-214, 2009.
23. D. A. Fitzmaurice, F.D. R. Hobbs, S. Jowett et al., "Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial, " British Medical Journal, vol. 335, no. 7616, pp. 383-386, 2007.
24. M. S. Labrador García, R. Merino Segovia, C. Jimenez Domínguez, Y. García Salvador, A. Segura Fragoso, and C. Hernández Lanchas, "Prevalence of auricular fibrillation in people over 65 years of age in a health area, " Atencion Primaria, vol. 28, no. 10, pp. 648-651, 2001.
25. P. Morillas, V. Pallares, J. L. Llisterri et al., "Prevalence of atrial fibrillation and use of antithrombotics in hypertensive patients aged ge;65 years. The FAPRES trial, " Revista Española de Cardiología (English Edition), vol. 63, no. 8, pp. 943-950, 2010.
26. L. Cea-Calvo, J. Redón, J. V. Lozano et al., "Prevalence of atrial fibrillation in the Spanishpopulationaged60years ormore. The PREV-ICTUS study, " Revista Espanola de Cardiologia, vol. 60, no. 6, pp. 616-624, 2007.
27. J. L. Clua-Espuny, "Atrial fibrillation and cardiovascular comorbidities, survival and mortality: a real-life observational study, " Cardiology Research, vol. 5, no. 1, pp. 12-22, 2014.
28. A. Majeed, K. Moser, and K. Carroll, "Trends in the prevalence and management of atrial fibrillation in general practice in England andWales, 1994-1998: analysis of data fromthe general practice research database, " Heart, vol. 86, no. 3, pp. 284-288, 2001.
29. P. D. Sobocinski, E. A. Rooth, V. F. Kull, M. von Arbin, H. Wallen, and M. Rosenqvist, "Improved screening for silent atrial fibrillation after ischaemic stroke, " Europace, vol. 14, no. 8, pp. 1112-1116, 2012.
30. C. Cowan, R. Healicon, I. Robson et al., "The use of anticoagulants in the management of atrial fibrillation among general practices in England, " Heart, vol. 99, pp. 1166-1172, 2013.
31. G. S. Yiin, D. P. Howard, N. L. Paul et al., "Age-specific incidence, outcome, cost, and projected future burden of atrial fibrillationrelated embolic vascular events: a population-based study, " Circulation, vol. 130, no. 15, pp. 1236-1244, 2014.
32. M. P. Rao, S. D. Pokorney, and C. B. Granger, "Atrial fibrillation: a review of recent studies with a focus on those from the Duke Clinical Research Institute, " Scientifica, vol. 2014, Article ID 901586, 11 pages, 2014.
33. I. M. Ogilvie, N. Newton, S. A. Welner, W. Cowell, and G. Y. H. Lip, "Underuse of oral anticoagulants in atrial fibrillation: a systematic review, " The American Journal of Medicine, vol. 123, no. 7, pp. 638.e4-645.e4, 2010.
34. N. Cohen, D. Almoznino-Sarafian, I. Alon et al., "Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission, " Stroke, vol. 31, no. 6, pp. 1217-1222, 2000.
35. E. Gimenez-García, J. L. Clua-Espuny, R. Bosch-Príncep et al., "El circuito asistencial de la fibrilación auricular en pacientes ambulatorios: estudio observacional Audit fibrilación auricular en el Baix Ebre, " Atención Primaria, vol. 46, no. 2, pp. 58-67, 2014.
36. D. E. Singer, A. S. Hellkamp, J. P. Piccini et al., "Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial, "The Journal of the American Heart Association, vol. 2, no. 1, Article ID e000067, 2013.
37. T. Wilke, A. Groth, S. Mueller et al., "Oral anticoagulation use by patients with atrial fibrillation inGermany: adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183, 448 patients, " Thrombosis and Haemostasis, vol. 107, no. 6, pp. 1053-1065, 2012.
38. A. Banerjee, N. Clementy, K. Haguenoer, L. Fauchier, and G. Y. Lip, "Prior history of falls and risk of outcomes in atrial fibrillation: the Loire Valley Atrial Fibrillation Project, " The American Journal of Medicine, vol. 127, no. 10, pp. 972-978, 2014.
39. P. Bahrmann, M. Wehling, D. Ropers, J. Flohr, A. Leischker, and J. Rother, "Optimal stroke prevention in the geriatric patient with atrial fibrillation: position paper of an interdisciplinary expert panel, " Drug Research, 2014.
40. M. B. Sellers and L. K. Newby, "Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients, " AmericanHeart Journal, vol. 161, no. 2, pp. 241-246, 2011.
41. S. D. Fihn, C. M. Callahan, D. C. Martin, M. B. McDonell, J. G. Henikoff, and R.H. White, "Therisk for and severity of bleeding complications in elderly patients treated with warfarin, " Annals of Internal Medicine, vol. 124, no. 11, pp. 970-979, 1996.
42. J. L. Clua-Espuny, J. L. Piñol-Moreso, A. Panisello-Tafalla et al., "La atención sanitaria del ictus en el área Terres de lEbre desde la implantación del Código Ictus. Estudio Ebrictus, " Medicina Clínica, vol. 138, no. 14, pp. 138-344, 2012.
43. M. Marcucci, G. Y. Lip, R. Nieuwlaat, R. Pisters, H. J. Crijns, and A. Iorio, "roke and bleeding risk co-distribution in realworld patients with atrial fibrillation: the Euro Heart Survey, " The American Journal of Medicine, vol. 127, no. 10, pp. 979.e2-986.e2, 2014.
44. K. I. Gallacher, G. Batty, G. McLean et al., "Stroke, multimorbidity and polypharmacy in a nationally representative sample of 1, 424, 378 patients in Scotland: implications for treatment burden, " BMC Medicine, vol. 12, article 151, 2014.
45. J. Ansell, J. Hollowell, V. Pengo, F. Martinez-Brotons, J. Caro, and L. Drouet, "Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the International Study of Anticoagulation Management (ISAM), " Journal of Thrombosis and Thrombolysis, vol. 23, no. 2, pp. 83-91, 2007.
46. T. Løkkegaard, T. H. Pedersen, B. Lind, V. Siersma, and F. B. Waldorff, "Good quality of oral anticoagulation treatment in general practice using international normalised ratio point of care testing, " Danish Medical Journal, vol. 62, no. 2, Article ID A5010, 2015.
47. F. Dentali, N. Riva, M. Crowther, A. G. G. Turpie, G. Y. H. Lip, and W. Ageno, "Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-Analysis of the literature, " Circulation, vol. 126, no. 20, pp. 2381-2391, 2012.
48. J. R. González-Juanatey, J. Alvarez-Sabin, J. M. Lobos et al., "Análisis coste-efectividad de dabigatrán para la prevención de ictus y embolia sistemica en fibrilación auricular no valvular en España, " Revista Española deCardiología, vol. 65, no. 10, pp. 901-910, 2012.
49. A. Janzic andM. Kos, "Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control, " PharmacoEconomics, 2014.
50. M. Wieloch, A. Sjlander, V. Frykman, M. Rosenqvist, N. Eriksson, and P. J. Svensson, "Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA, " European Heart Journal, vol. 32, no. 18, pp. 2282-2289, 2011.
51. C. T. Ruff, R. P. Giugliano, E. Braunwald et al., "Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: ameta-Analysis of randomised trials, " The Lancet, vol. 383, no. 9921, pp. 955-962, 2014.